Red Flags Detected

  • Going Concern (new) — Auditor added substantial-doubt going-concern paragraph in FY2025 opinion; FY2024 opinion contained only an emphasis-of-matter paragraph without substantial-doubt language.
  • Securities Litigation (worsened) — Class period expanded from 5 months to 19 months; new allegations added regarding product safety and financial condition.
NASDAQ: HUMAW Humacyte, Inc. 10-K

Humacyte launches Symvess with $1.4M revenue, $9.7M COGS; auditor flags going concern

Filed March 27, 2026 · Period ending December 31, 2025 · Compared to 10-K Mar 31, 2025 · ~2 min read

Key Changes

  • high

    Auditor added substantial-doubt going-concern opinion for FY2025; company states it cannot fund operations beyond one year without additional capital or commercial revenue growth.

    Notes: Going Concern verify on EDGAR →
  • high

    Securities class action expanded from 5-month to 19-month class period; new allegations include product safety, manufacturing deficiencies, and financial condition misstatements.

    Legal Proceedings verify on EDGAR →
  • high

    First product revenue of $1.4M offset by $9.7M cost of goods sold (including $8.9M inventory write-down), yielding negative gross margin in initial commercialization.

    MD&A: Revenue & COGS verify on EDGAR →

2 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.

Read 3 full reports/month free No card required. Takes 30 seconds.

Want to see a complete report first? Today's free report (SMID 10-Q) is open in full — no account needed.

Partner

Trade HUMAW commission-free

Open an account, get a free stock.

Sign up

Investing involves risk. Free stock terms apply.

View original filing on SEC.gov View full financials on EDGAR ↗

Generated by AI · Jun 11, 2026 3:22 AM